Mostrando 10 resultados de: 10
Subtipo de publicación
Article(10)
Publisher
New England Journal of Medicine(3)
Gastroenterology(2)
American Heart Journal(1)
Canadian Journal of Cardiology(1)
Diabetes Care(1)
Basal insulin and cardiovascular and other outcomes in dysglycemia
ArticleAbstract: Background: The provision of sufficient basal insulin to normalize fasting plasma glucose levels mayPalabras claves:Autores:Abdallah A., Ahmad S., AHUAD GUERRERO R.A., Alebuena A., Alvarez N., Alzogaray M., Amuchastegui M., Andres M., Angos M., Avezum A.J., Baglivo H., Bahit M.C., Barbieri M., Bassi F., Bello F., Birkeland K.I., Bogaty P.M., Bono J., Bordeleau L., Bosch J.J., Budaj A.J., Bustamante Labarta M., Bustos B., Cardona E., Chacόn C., Chandra J., Chandra R., Chazova I.E., Commerford P.J., Corson M., Cukierman-Yaffee T., Dagenais G.R., Danilova L., Davies M., Díaz R., Dyal L., Fernando R., Fodor G.J., Gerstein H.C., Gilbert R., Gomis R., Halon D., Hâncu N., Hanefeld M., Harper W.L., Hildebrandt P., Johnston P., Joldersma L., Jung H., Kacerovsky-Bielesz G., Keltai M., Kim J.H., Krum H., Kultursay H., Lanas F.T., Lewis B.S., Lonn E.M., MacRae L., MacRae S., Maggioni A.P., Magloire P., Malik S., Mann J.F.E., Marin-Neto J.A., Marre M., McKelvie R., McQueen M.J., Mead A., Mendoza I., Morillo C.A., Pan C., Pasha F., PATRICIO LOPEZ -JARAMILLO, Pavlova V., Pazmino-Canizares J., Pirags V., Pogue J., Pohl K., Probstfield J.L., Profozic V., Punthakee Z., Ramachandran A., Ratner R., Richardson L., Riddle M.C., Rosenstock J., Rydén L.E., Sakalas A., Silva J., Spinas G.A., Sreenan S., Stoel I., Syvänne M., Tsang B., Tyrwhitt J., Vige R., Yakubovich N., Yale J.F., Yusuf S.Fuentes:scopusCardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids (ORIGINALE)
ArticleAbstract: OBJECTIVE: The Outcome Reduction With Initial Glargine Intervention (ORIGIN) trial reported neutralPalabras claves:Autores:Abdallah A., Ahmad S., AHUAD GUERRERO R.A., Alebuena A., Alvarez N., Alzogaray M., Amuchastegui M., Andres M., Angos M., Avezum A.J., Baglivo H., Bahit M.C., Barbieri M., Bassi F., Bello F., Birkeland K.I., Bogaty P.M., Bono J., Bordeleau L., Bosch J.J., Budaj A.J., Bustamante Labarta M., Bustos B., Cardona E., Chacόn C., Chandra J., Chandra R., Chazova I.E., Commerford P.J., Corson M., Cukierman-Yaffee T., Dagenais G.R., Danilova L., Davies M., DIaz R., Dyal L., Fernando R., Fodor G.J., Gerstein H.C., Gilbert R., Gomis R., Halon D., Hâncu N., Hanefeld M., Harper W.L., Hildebrandt P., Johnston P., Joldersma L., Jung H., Kacerovsky-Bielesz G., Keltai M., Kim J.H., Krum H., Kultursay H., Lanas F., Lewis B.S., Lonn E.M., MacRae L., MacRae S., Maggioni A.P., Magloire P., Malik S., Mann J.F.E., Marin-Neto J.A., Marre M., McKelvie R., McQueen M.J., Mead A., Mendoza I., Morillo C.A., Pan C., Pasha F., PATRICIO LOPEZ -JARAMILLO, Pavlova V., Pazmino-Canizares J., Pirags V., Pogue J., Pohl K., Probstfield J.L., Profozic V., Punthakee Z., Ramachandran A., Ratner R., Richardson L., Riddle M.C., Rosenstock J., Rydén L.E., Sakalas A., Silva J., Spinas G.A., Sreenan S., Stoel I., Syvänne M., Tsang B., Tyrwhitt J., Vige R., Yakubovich N., Yale J.F., Yusuf S.Fuentes:scopusN-3 fatty acids and cardiovascular outcomes in patients with dysglycemia
ArticleAbstract: Background: The use of n-3 fatty acids may prevent cardiovascular events in patients with recent myoPalabras claves:Autores:Abdallah A., Ahmad S., AHUAD GUERRERO R.A., Alebuena A., Alvarez N., Alzogaray M., Amuchastegui M., Andres M., Angos M., Avezum A.J., Baglivo H., Bahit M.C., Barbieri M., Bassi F., Bello F., Birkeland K.I., Bogaty P.M., Bono J., Bordeleau L., Bosch J.J., Budaj A.J., Bustamante Labarta M., Bustos B., CACCAVO A., Cardona E., Chacόn C., Chandra J., Chandra R., Chazova I.E., Commerford P.J., Corson M., Cukierman-Yaffee T., Dagenais G.R., Danilova L., Davies M., DIaz R., Dyal L., Fernando R., Fodor G.J., Gerstein H.C., Gilbert R., Gomis R., Halon D., Hâncu N., Hanefeld M., Harper W.L., Hildebrandt P., Johnston P., Joldersma L., Jung H., Kacerovsky-Bielesz G., Keltai M., Kim J.H., Krum H., Kultursay H., Lanas F.T., Lewis B.S., Lonn E.M., MacRae L., MacRae S., Maggiono A.P., Magloire P., Malik S., Mann J.F.E., Marin-Neto J.A., Marre M., McKelvie R., McQueen M.J., Mead A., Mendoza I., Morillo C.A., Pan C., Pasha F., PATRICIO LOPEZ -JARAMILLO, Pavlova V., Pazmino-Canizares J., Pirags V., Pohl K., Probstfield J.L., Profozic V., Punthakee Z., Ramachandran A., Ratner R., Richardson L., Riddle M.C., Rosenstock J., Rydén L.E., Sakalas A., Silva J., Spinas G.A., Sreenan S., Stoel I., Syvänne M., Tsang B., Tyrwhitt J., Vige R., Yakubovich N., Yale J.F., Yusuf S.Fuentes:scopusPantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial
ArticleAbstract: Background & Aims: Antiplatelets and anticoagulants are associated with increased upper gastrointestPalabras claves:drug, Heart Disease Prevention, Stomach, ThrombosisAutores:Alings M., Anand S.S., Avezum A.J., Bhatt D.L., Bosch J.J., Branch K.R.H., Commerford P.J., Connolly S.J., Cook-Bruns N., Dagenais G.R., Dans A.M., DIaz R., Dyal L., Eikelboom J.W., Ertl G., Felix Camilo, Fox K.A.A., Guzik T.J., Hart R.G., Hori M., Kakkar A.K., Keltai M., Kim J.H., Lanas F.T., Leong D.P., Lewis B.S., Liang Y., Lonn E.M., Maggioni A.P., Metsarinne K.P., Moayyedi P., Muehlhofer E., O’Donnell M., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Shestakovska O., Steg P.G., Störk S., Tonkin A.M., Torp-Pedersen C., Verhamme P.B., Vinereanu D., Widimsky P., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusLong-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial
ArticleAbstract: Aims: To describe outcomes of patients with chronic coronary artery disease (CAD) and/or peripheralPalabras claves:aspirin, Coronary artery disease, Peripheral artery disease, rivaroxabanAutores:Aboyans V., Alings M., Anand S.S., Avezum A.J., Bangdiwala S.I., Bhatt D.L., Bosch J.J., Branch K.R.H., Camillo Felix, Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.L., DIaz R., Eikelboom J.W., Ertl G., Fox K.A.A., Guzik T.J., Hori M., Ibrahim K.S., Kakkar A.K., Keltai K., Keltai M., Kim J.H., Lamy A., Lanas F., Leong D.P., Lewis B.S., Liang Y., Lonn E.M., Lopez-Jaramillo P., Maggioni A.P., Metsarinne K.P., Muehlhofer E., Neumann C., O’Donnell M., Parkhomenko A.N., Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Sharma M., Steg P.G., Stoerk S., Tasto C., Tonkin A.M., Torp-Pedersen C., Tyrwitt J., Vanassche T., Varigos J.D., Verhamme P.B., Vinereanu D., Widimsky P., Yusuf S., Zhu J.Fuentes:scopusSafety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
ArticleAbstract: Background & Aims: Proton pump inhibitors (PPIs) are effective at treating acid-related disorders. TPalabras claves:bacteria, CVD, Reflux, ThrombosisAutores:Alings M., Anand S.S., Avezum A.J., Bhatt D.L., Bosch J.J., Branch K.R.H., Bruns N.C., Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.M., DIaz R., Dyal L., Eikelboom J.W., Ertl G., Felix Camilo, Fox K.A.A., Guzik T.J., Hart R.G., Hori M., Kakkar A.K., Keltai M., Kim J.H., Lanas F.T., Leong D.P., Lewis B.S., Liang Y., Lonn E.M., Maggioni A.P., Metsarinne K.P., Moayyedi P., Muehlhofer E., O’Donnell M., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Shestakovska O., Steg P.G., Störk S., Tonkin A.M., Torp-Pedersen C., Verhamme P.B., Vinereanu D., Widimsky P., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusRationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial
ArticleAbstract: Background Long-term aspirin prevents vascular events but is only modestly effective. Rivaroxaban alPalabras claves:Autores:Aboyans V., Alings M., Anand S.S., Avezum A.J., Bhatt D.L., Bosch J.J., Branch K.R.H., Bruns N.C., Chen E., Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.M., DIaz R., Eikelboom J.W., Ertl G., Felix Camilo, Fox K.A.A., Guzik T.J., Ha J.W., Hart R.G., Hori M., Kakkar A.K., Keltai K., Keltai M., Kim J.H., Lamy A., Lanas F., Lanius V., Leong D.P., Lewis B.S., Liang Y., Liu L., Lonn E.M., Maggioni A.P., Metsarinne K.P., Misselwitz F., Moayyedi P., O’Donnell M., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Sharma M., Steg P.G., Störk S., Tonkin A.M., Torp-Pedersen C., Varigos J.D., Verhamme P.B., Vinereanu D., Widimsky P., Yuan F., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusRationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention)
ArticleAbstract: Aims Impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and diabetes arise due to insPalabras claves:Autores:Accatoli A., AHUAD GUERRERO R.A., Alvarez C., Alvarisqueta A., Amuchastegui M., Angos M., Ankudowikz V., Arias P., Baglivo H., Bagur R., Baigorria A., Baselga P., Bello F., Bertrand B., Birkeland K.I., Bono J., Bosch J.J., Brito S., Budaj A.J., Bustamante Labarta M., Bustos B., Buzeki R., Cabut A.M., CACCAVO A., Cantalupi H., Canteros M.C., Capozzi M.N., Cardona E., Cardone M., CARTASEGNA L.U.I.S., Cassetari A., Castano P., Castellanos R., Cerdan M.A., Chazova I.E., Cismondi M.T., Commerford P.J., Contreras A., Coria G., Corinaldesi F., Costa G., Costa Vitali A., Crespo C., Cruz M., Cuello J.L., Cuneo C.A., Dagenais G.R., Danilova L., Davies M., De Loredo L., De Maria M., Denaro R., Devoto C., Díaz R., Faingold C., Falu R., Fernando R., Fodor G.J., Gamiz J., Gerstein H.C., Gilbert R., Gomis R., Hâncu N., Hanefeld M., Hildebrandt P., Johnston P., Kacerovsky-Bielesz G., Keltai M., Kim J., Krum H., Kultursay H., Lanas F.T., Lewis B.S., Lonn E.M., Maggioni A.P., Marin-Neto J.A., Marre M., McKelvie R., McQueen M.J., Mendoza I., Morillo C.A., Pan C., PATRICIO LOPEZ -JARAMILLO, Pirags V., Probstfield J.L., Profozic V., Ramachandran A., Ratner R., Richardson L., Riddle M.C., Rosenstock J., Rouleau J.L., Rydén L.E., Spinas G.A., Sreenan S., Stoel I., Syvänne M., Vige R., Yale J.F., Yusuf S.Fuentes:scopusRivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial
ArticleAbstract: Background: Patients with peripheral artery disease have an increased risk of cardiovascular morbidiPalabras claves:Autores:Aboyans V., ABRANTES J.A., AHUAD GUERRERO R.A., ALBISU DI GENNERO J.P., Alings M., ALVAREZ M., Anand S.S., Avezum A.J., Bangdiwala S.I., Barbieri M., BARTOLACCI I.P., Bhatt D.L., BORDONAVA A.P., Bosch J.J., Branch K.R.H., CACCAVO A., CARDONA M., CARTASEGNA L.U.I.S., Chacón C., Chen E., Commerford P.J., Connolly S.J., COSTABEL J.P., CUADRADO J., Cuneo C.A., DEBONNAIRE P., DIaz R., DRAN R.D., DUJARDIN K.A.R.L., ECTOR B.A.V.O., Eikelboom J.W., ELEGEERT I.V.A.N., FERRE PACORA F.A., Fox K.A.A., GARCIA DURAN R.O., GARRIDO M., Gomez Vilamajo O., GONZALEZ COLASO P.D.C., GRINFELD D., GUZMAN L.U.I.S., Hart R.G., HASBANI E., HERNANDES M., HOFFER E., HOMINAL M.A., HRABAR A., IBANEZ SAGGIA L.M., INDIO DO BRASIL C., Ingaramo A., Kakkar A.K., Keltai K., Leong D.P., LEROY J.E.A.N., Lewis B.S., LITVAK BRUNO M.R., LUCIARDI H.L., LUQUEZ H.U.G.O., MACIN S.M., MACKINNON I.J., MAFFEI L.E., Maggioni A.P., Maia L.N., MAJUL C.R., MANENTI E., Misselwitz F., Montaña O., NANI S., Novaretto L., O’Donnell M., PATRICIO LOPEZ -JARAMILLO, PELAGAGGE M.J., Pogosova N., Precoma D.B., Reis G., ROSSI DOS SANTOS F., ROSSI P., Rydén L.E., SALA J., SARAIVA J.O.S.E., SARJANOVICH R.J., SCHIAVI L.B., SCHROE H., SCHYGIEL P.O., Störk S., VAN DE BORNE P., VAN DEN HEUVEL P.A.U.L., Vanassche T., Varigos J.D., VENSENTINI N., Verhamme P.B., VICO M., Vinereanu D., VITA N.A., VOGEL D., VRANCKX P., Widimsky P., Yan Duarte, Yusuf S., ZAIDMAN C., Zhu J., ZIMMERMANN S.L.Fuentes:scopusRivaroxaban with or without aspirin in stable cardiovascular disease
ArticleAbstract: BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effePalabras claves:Autores:Aboyans V., Alings M., Anand S.S., Avezum A.J., Bangdiwala S.I., Bhagirath V., Bhatt D.L., Bogaty P.M., Bosch J.J., Botto F., Branch K.R.H., Bruns N.C., Cairns J., Carlos Ernesto Peñaherrera, Casanova A., Catanese L., Chen E., Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.M., DeMets D., Deng E., DIaz R., Donato Magno J., Edgar B. Rodas, Eikelboom J.W., Ertl G., Fabbri G., Felix Camilo, Fox K.A.A., Gabizon I., Gosselin G., Goto S., Guzik T.J., Ha J., Halon D., Hart R.G., Heldmann M., Hori M., Kakkar A.K., Keltai K., Keltai M., Kim J.H., Lamelas P.M., Lamy A., Lanas F., Lauw M., Leong D.P., Leong Y., Lewis B.S., Liang D., Liang Y., Liu L., Lonn E.M., Lutay Y., Maggioni A.P., Maly M., María José Paucar, Metsarinne K.P., Mikulik R., Misselwitz F., Moayyedi P., Momomura S.I., Nayar S., Ng K., O’Donnell M., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Perera K., Piegas L.S., Pirvu O., Pogosova N., Prins M., Probstfield J.L., Ramsay T., Ronner E., Rouleau J.L., Rydén L.E., Sato S., Schumi J., Sharma M., Shestakovska O., Shirley Guamán, Silvia Cáceres, Sleight P., Smyth A., Sokolova E., Steg P.G., Stoerk S., Störk S., Thabane L., Tonkin A.M., Torp-Pedersen C., Varigos J.D., Verhamme P.B., Vinereanu D., Widimsky P., Wiendl M., Winkelmann B., Yan Duarte, Yang X., Yufereva Y., Yusoff K., Yusuf S., Zhu J.Fuentes:scopus